From the Editor

Crashing into progress: New findings meet old habits

Alicia Morgans
July 27, 2017

In the last few weeks I have talked with numerous colleagues about the findings from LATITUDE and STAMPEDE presented recently at the ASCO Annual Meeting and published in the New England Journal of Medicine in June 2017.  We find ourselves in the process of integrating the findings into a treatment landscape that is still grappling with the findings of CHAARTED, data demonstrating a survival benefit from the use of chemohormonal therapy in a similar high risk population of men with metastatic hormone sensitive prostate cancer (mHSPC) first presented only a few years ago. 

READ MORE PREVIOUS ARTICLES

Alicia Morgans, MD

Alicia Morgans, MD, MPH

Alicia Morgans, MD, MPH is an Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. She completed her MD and internal medicine residency at the University Of Pennsylvania Perelman School Of Medicine, and her fellowship at Dana Farber Cancer Institute/MGH Cancer Center. She is a clinician and physician investigator specializing is investigating complications of systemic therapy for prostate cancer survivors. Her work has included the study of skeletal, cardiovascular, diabetic, and cognitive complications of prostate cancer survivorship, as well as treatment decision making in the metastatic prostate cancer population. She has expertise in clinical trials and patient reported outcome measures, and as well as incorporating patient preferences and beliefs into clinical decision making.

Video Lectures
State-of-the-industry video lectures by leading urology experts
@UroToday